Skip to main content
Erschienen in: Current Colorectal Cancer Reports 2/2013

01.06.2013 | Localized Rectal Cancer (R Glynne-Jones, Section Editor)

Colorectal Cancer in the Elderly: How Do We Tailor Treatment with Chemotherapy and Radiotherapy Most Appropriately?

verfasst von: Demetris Papamichael, Rob Glynne-Jones

Erschienen in: Current Colorectal Cancer Reports | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

Colorectal cancer is the commonest malignancy in patients aged 75 years or older. The incidence is likely to rise further over the next two decades as the population ages and survival increases. Robust data on the adherence to guidelines for the elderly and the uptake of treatment in the elderly are limited—particularly with regard to rectal cancer. However, the evidence available suggests that clinical attitudes observed regarding age and cancer treatment are consistent. Older people with colorectal cancer tend to be offered either less intensive treatment or no treatment at all. Population data confirm that treatment rates for surgery, chemotherapy and radiotherapy in patients with colorectal cancer all decline for those over 70 years old, and continue to decline exponentially with increasing age. So should new, more tolerable strategies which may avoid radical surgery be more widely available (short-course preoperative radiotherapy, chemoradiotherapy, transanal excision microsurgery, brachytherapy, contact therapy)? It is not clear if oncologists are always making the most appropriate management decisions. So how do oncologists and surgeons balance chronological age, comorbidity, social isolation and other influences in their clinical decision-making? We need to recognise that this is a difficult issue and will be an increasing issue for multidisciplinary teams.
Literatur
1.
3.
Zurück zum Zitat Martijn H, Vulto JC. Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer. 2007;43(15):2301–6.PubMedCrossRef Martijn H, Vulto JC. Should radiotherapy be avoided or delivered differently in elderly patients with rectal cancer? Eur J Cancer. 2007;43(15):2301–6.PubMedCrossRef
4.
Zurück zum Zitat • Papamichael D, Audisio R, Horiot JC, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009;20(1):5–16. This is the first set of recommendations produced by the International Society of Geriatric Oncology specifically for managing CRC in the elderly. PubMedCrossRef • Papamichael D, Audisio R, Horiot JC, et al. Treatment of the elderly colorectal cancer patient: SIOG expert recommendations. Ann Oncol. 2009;20(1):5–16. This is the first set of recommendations produced by the International Society of Geriatric Oncology specifically for managing CRC in the elderly. PubMedCrossRef
6.
Zurück zum Zitat Lichtman SM. Management of advanced colorectal cancer in older patients. Oncology. 2005;19(5):597–602.PubMed Lichtman SM. Management of advanced colorectal cancer in older patients. Oncology. 2005;19(5):597–602.PubMed
7.
Zurück zum Zitat Tan E, Tilney H, Thompson M, Smith J, Tekkis PP. The United Kingdom National Bowel Cancer Project – epidemiology and surgical risk in the elderly. Eur J Cancer. 2007;43(15). Tan E, Tilney H, Thompson M, Smith J, Tekkis PP. The United Kingdom National Bowel Cancer Project – epidemiology and surgical risk in the elderly. Eur J Cancer. 2007;43(15).
9.
Zurück zum Zitat •• Manceau G, Karoui M, Werner A, Mortensen NJ, Hannoun L. Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review. Lancet Oncol. 2012;13(12):E525–36. Following a systematic review, the authors conclude that the level of evidence for most studies was weak, emphasising the need for high-quality clinical trials for this population. PubMedCrossRef •• Manceau G, Karoui M, Werner A, Mortensen NJ, Hannoun L. Comparative outcomes of rectal cancer surgery between elderly and non-elderly patients: a systematic review. Lancet Oncol. 2012;13(12):E525–36. Following a systematic review, the authors conclude that the level of evidence for most studies was weak, emphasising the need for high-quality clinical trials for this population. PubMedCrossRef
10.
Zurück zum Zitat Morris E, Quirke P, Thomas JD, et al. Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? Gut. 2008;57(12):1690–7.PubMedCrossRef Morris E, Quirke P, Thomas JD, et al. Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? Gut. 2008;57(12):1690–7.PubMedCrossRef
12.
Zurück zum Zitat Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693–701.PubMedCrossRef Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T, et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg. 2007;246(5):693–701.PubMedCrossRef
13.
Zurück zum Zitat Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomized trial. Lancet. 2009;811–20. Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomized trial. Lancet. 2009;811–20.
14.
Zurück zum Zitat van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Dutch Colorectal Cancer Group et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomized controlled TME trial. Lancet Oncol. 2011;12(6):575–82.PubMedCrossRef van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Dutch Colorectal Cancer Group et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomized controlled TME trial. Lancet Oncol. 2011;12(6):575–82.PubMedCrossRef
15.
Zurück zum Zitat Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.PubMedCrossRef Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731–40.PubMedCrossRef
16.
Zurück zum Zitat Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.PubMedCrossRef Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114–23.PubMedCrossRef
17.
Zurück zum Zitat Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.PubMedCrossRef Gerard JP, Conroy T, Bonnetain F, Bouche O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24:4620–5.PubMedCrossRef
18.
Zurück zum Zitat Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Alegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R03. J Clin Oncol. 2009;27:5124–30.PubMedCrossRef Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Alegra CJ, et al. Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R03. J Clin Oncol. 2009;27:5124–30.PubMedCrossRef
19.
Zurück zum Zitat Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251(5):807–18.PubMedCrossRef Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg. 2010;251(5):807–18.PubMedCrossRef
20.
Zurück zum Zitat Borowski DW, Bradburn DM, Mills SJ, Bharathan B, Wilson RG, Ratcliffe AA, et al. Volume-outcome analysis of colorectal cancer-related outcomes. Br J Surg. 2010;97:1416–30.PubMedCrossRef Borowski DW, Bradburn DM, Mills SJ, Bharathan B, Wilson RG, Ratcliffe AA, et al. Volume-outcome analysis of colorectal cancer-related outcomes. Br J Surg. 2010;97:1416–30.PubMedCrossRef
21.
Zurück zum Zitat Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9(5):494–501.PubMedCrossRef Rutten HJ, den Dulk M, Lemmens VE, van de Velde CJ, Marijnen CA. Controversies of total mesorectal excision for rectal cancer in elderly patients. Lancet Oncol. 2008;9(5):494–501.PubMedCrossRef
22.
Zurück zum Zitat Gervaz PA, Wexner SD, Pemberton JH. Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy. J Am Coll Surg. 2002;195:387–94.PubMedCrossRef Gervaz PA, Wexner SD, Pemberton JH. Pelvic radiation and anorectal function: introducing the concept of sphincter-preserving radiation therapy. J Am Coll Surg. 2002;195:387–94.PubMedCrossRef
23.
Zurück zum Zitat Bujko K, Nowacki MP, Nasierowska-Guttmejer A. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.PubMedCrossRef Bujko K, Nowacki MP, Nasierowska-Guttmejer A. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;93(10):1215–23.PubMedCrossRef
24.
Zurück zum Zitat Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc. 1991;39(9 Pt 2):16. Rubenstein LZ, Stuck AE, Siu AL, Wieland D. Impacts of geriatric evaluation and management programs on defined outcomes: overview of the evidence. J Am Geriatr Soc. 1991;39(9 Pt 2):16.
25.
Zurück zum Zitat Stuck AE, Siu AL, Wieland GD, Rubenstein LZ, Adams J. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342(8878):1032–6.PubMedCrossRef Stuck AE, Siu AL, Wieland GD, Rubenstein LZ, Adams J. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993;342(8878):1032–6.PubMedCrossRef
26.
28.
Zurück zum Zitat Kalata P, Martus P, Zettl H, Rödel C, Hohenberger W, Raab R, et al. Differences between clinical trial participants and patients in a population-based registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry. Dis Colon Rectum. 2009;52(3):425–37.PubMedCrossRef Kalata P, Martus P, Zettl H, Rödel C, Hohenberger W, Raab R, et al. Differences between clinical trial participants and patients in a population-based registry: the German Rectal Cancer Study vs. the Rostock Cancer Registry. Dis Colon Rectum. 2009;52(3):425–37.PubMedCrossRef
29.
Zurück zum Zitat Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.PubMedCrossRef Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.PubMedCrossRef
30.
Zurück zum Zitat Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age based disparities. JAMA. 2004;291:2720–6.PubMedCrossRef Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age based disparities. JAMA. 2004;291:2720–6.PubMedCrossRef
31.
Zurück zum Zitat Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23(13):3112–24.PubMedCrossRef Townsley CA, Selby R, Siu LL. Systematic review of barriers to the recruitment of older patients with cancer onto clinical trials. J Clin Oncol. 2005;23(13):3112–24.PubMedCrossRef
32.
Zurück zum Zitat Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011;26(7):783–90.PubMedCrossRef Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med. 2011;26(7):783–90.PubMedCrossRef
33.
Zurück zum Zitat McMurdo ME, Roberts H, Parker S, et al. Improving recruitment of older people to research through good practice. Age Ageing. 2011;40(6):659–65.PubMedCrossRef McMurdo ME, Roberts H, Parker S, et al. Improving recruitment of older people to research through good practice. Age Ageing. 2011;40(6):659–65.PubMedCrossRef
34.
Zurück zum Zitat Anonymous. Initial report from a Swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Swedish Rectal Cancer Trial. Br J Surg. 1993;80:1333–6. Anonymous. Initial report from a Swedish multicentre study examining the role of preoperative irradiation in the treatment of patients with resectable rectal carcinoma. Swedish Rectal Cancer Trial. Br J Surg. 1993;80:1333–6.
35.
Zurück zum Zitat Townsley CA, Chan KK, Pond GR, et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 2006;6:34.PubMedCrossRef Townsley CA, Chan KK, Pond GR, et al. Understanding the attitudes of the elderly towards enrolment into cancer clinical trials. BMC Cancer. 2006;6:34.PubMedCrossRef
36.
Zurück zum Zitat • Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377(9779):1749–59. This is probably the first trial in metastatic CRC targeting this patient population and showing that it is feasible to do so. PubMedCrossRef • Seymour MT, Thompson LC, Wasan HS, Middleton G, Brewster AE, Shepherd SF, et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet. 2011;377(9779):1749–59. This is probably the first trial in metastatic CRC targeting this patient population and showing that it is feasible to do so. PubMedCrossRef
37.
Zurück zum Zitat Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–7.PubMedCrossRef Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091–7.PubMedCrossRef
38.
Zurück zum Zitat Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–91.PubMedCrossRef Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085–91.PubMedCrossRef
39.
Zurück zum Zitat Pignon T, Horiot JC, Bolla M, van Poppel H, Bartelink H, Roelofsen F, et al. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol. 1997;42(2):107–20.PubMedCrossRef Pignon T, Horiot JC, Bolla M, van Poppel H, Bartelink H, Roelofsen F, et al. Age is not a limiting factor for radical radiotherapy in pelvic malignancies. Radiother Oncol. 1997;42(2):107–20.PubMedCrossRef
40.
Zurück zum Zitat Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33.PubMedCrossRef Ngan SY, Burmeister B, Fisher RJ, Solomon M, Goldstein D, Joseph D, et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol. 2012;30(31):3827–33.PubMedCrossRef
41.
Zurück zum Zitat Leonard R, Ballinger R, Cameron D, Ellis P, Fallowfield L, Gosney M, et al. Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br J Cancer. 2011;105(9):1260–6.PubMedCrossRef Leonard R, Ballinger R, Cameron D, Ellis P, Fallowfield L, Gosney M, et al. Adjuvant chemotherapy in older women (ACTION) study - what did we learn from the pilot phase? Br J Cancer. 2011;105(9):1260–6.PubMedCrossRef
42.
Zurück zum Zitat Paszat LF, Brundage MD, Groome PA, Schulze K, Mackillop WJ. A population-based study of rectal cancer: permanent colostomy as an outcome. Int J Radiat Oncol Biol Phys. 1999;45(5):1185–91.PubMedCrossRef Paszat LF, Brundage MD, Groome PA, Schulze K, Mackillop WJ. A population-based study of rectal cancer: permanent colostomy as an outcome. Int J Radiat Oncol Biol Phys. 1999;45(5):1185–91.PubMedCrossRef
43.
Zurück zum Zitat Faivre-Finn C, Benhamiche AM, Maingon P, et al. Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population. Radiother Oncol. 2000;57:137–42.PubMedCrossRef Faivre-Finn C, Benhamiche AM, Maingon P, et al. Changes in the practice of adjuvant radiotherapy in resectable rectal cancer within a French well-defined population. Radiother Oncol. 2000;57:137–42.PubMedCrossRef
44.
Zurück zum Zitat Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results—Medicare. J Clin Oncol. 2001;19(17):3712–8.PubMed Schrag D, Gelfand SE, Bach PB, Guillem J, Minsky BD, Begg CB. Who gets adjuvant treatment for stage II and III rectal cancer? Insight from surveillance, epidemiology, and end results—Medicare. J Clin Oncol. 2001;19(17):3712–8.PubMed
45.
Zurück zum Zitat Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. Ann Surg. 2001;234(5):641–51.PubMedCrossRef Schroen AT, Cress RD. Use of surgical procedures and adjuvant therapy in rectal cancer treatment: a population-based study. Ann Surg. 2001;234(5):641–51.PubMedCrossRef
46.
Zurück zum Zitat Neugut AI N, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20:2643–50.PubMedCrossRef Neugut AI N, Fleischauer AT, Sundararajan V, et al. Use of adjuvant chemotherapy and radiation therapy for rectal cancer among the elderly: a population-based study. J Clin Oncol. 2002;20:2643–50.PubMedCrossRef
47.
Zurück zum Zitat Dharma-Wardene MW, de Gara C, Au HJ, Hanson J, Hatcher J. Ageism in rectal carcinoma? Treatment and outcome variations. Int J Gastrointest Canc. 2002;32(2–3):129–3.CrossRef Dharma-Wardene MW, de Gara C, Au HJ, Hanson J, Hatcher J. Ageism in rectal carcinoma? Treatment and outcome variations. Int J Gastrointest Canc. 2002;32(2–3):129–3.CrossRef
48.
Zurück zum Zitat Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–300.PubMedCrossRef Ayanian JZ, Zaslavsky AM, Fuchs CS, et al. Use of adjuvant chemotherapy and radiation therapy for colorectal cancer in a population-based cohort. J Clin Oncol. 2003;21:1293–300.PubMedCrossRef
49.
Zurück zum Zitat Phelip JM, Milan C, Herbert C, Grosclaude P, Arveux P, Raverdy N, et al. Evaluation of the management of rectal cancers before and after the consensus conference in France. Eur J Gastroenterol Hepatol. 2004;16(10):1003–9.PubMedCrossRef Phelip JM, Milan C, Herbert C, Grosclaude P, Arveux P, Raverdy N, et al. Evaluation of the management of rectal cancers before and after the consensus conference in France. Eur J Gastroenterol Hepatol. 2004;16(10):1003–9.PubMedCrossRef
50.
Zurück zum Zitat Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol. 2007;25(8):1014–20.PubMedCrossRef Baxter NN, Garcia-Aguilar J. Organ preservation for rectal cancer. J Clin Oncol. 2007;25(8):1014–20.PubMedCrossRef
51.
Zurück zum Zitat Vulto AJ, Lemmens VE, Louwman MW, et al. The influence of age and co-morbidity on receiving radiotherapy as part of primary treatment for cancer in south Netherlands, 1995–2002. Cancer. 2006;106:2734–42.PubMedCrossRef Vulto AJ, Lemmens VE, Louwman MW, et al. The influence of age and co-morbidity on receiving radiotherapy as part of primary treatment for cancer in south Netherlands, 1995–2002. Cancer. 2006;106:2734–42.PubMedCrossRef
52.
Zurück zum Zitat Endreseth BH, Romundstad P, Myrvold HE, Bjerkeset T, Wibe A, Norwegian Rectal Cancer Group. Rectal cancer treatment of the elderly. Colorectal Dis. 2006;8(6):471–9.PubMedCrossRef Endreseth BH, Romundstad P, Myrvold HE, Bjerkeset T, Wibe A, Norwegian Rectal Cancer Group. Rectal cancer treatment of the elderly. Colorectal Dis. 2006;8(6):471–9.PubMedCrossRef
53.
Zurück zum Zitat Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M. Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg. 2007;246(2):215–21.PubMedCrossRef Chang GJ, Skibber JM, Feig BW, Rodriguez-Bigas M. Are we undertreating rectal cancer in the elderly? An epidemiologic study. Ann Surg. 2007;246(2):215–21.PubMedCrossRef
54.
Zurück zum Zitat Jung B, Påhlman L, Johansson R, Nilsson E. Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish Rectal Cancer Registry 1995–2004. BMC Cancer. 2009;9:68.PubMedCrossRef Jung B, Påhlman L, Johansson R, Nilsson E. Rectal cancer treatment and outcome in the elderly: an audit based on the Swedish Rectal Cancer Registry 1995–2004. BMC Cancer. 2009;9:68.PubMedCrossRef
55.
Zurück zum Zitat Gagliardi G, Pucciarelli S, Asteria CR, et al. A nationwide audit of the use of radiotherapy for rectal cancer in Italy. Tech Coloproctol. 2010;14(3):229–35.PubMedCrossRef Gagliardi G, Pucciarelli S, Asteria CR, et al. A nationwide audit of the use of radiotherapy for rectal cancer in Italy. Tech Coloproctol. 2010;14(3):229–35.PubMedCrossRef
56.
Zurück zum Zitat Quipourt V, Jooste V, Cottet V, Faivre J, Bouvier AM. Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. J Am Geriatr Soc. 2011;59(4):694–8.PubMedCrossRef Quipourt V, Jooste V, Cottet V, Faivre J, Bouvier AM. Comorbidities alone do not explain the undertreatment of colorectal cancer in older adults: a French population-based study. J Am Geriatr Soc. 2011;59(4):694–8.PubMedCrossRef
57.
Zurück zum Zitat Kutner JS, Vu KO, Prindiville SA, et al. Patient age and cancer treatment decisions. Patient and physician views. Canc Pract. 2000;8(3):114–9.CrossRef Kutner JS, Vu KO, Prindiville SA, et al. Patient age and cancer treatment decisions. Patient and physician views. Canc Pract. 2000;8(3):114–9.CrossRef
58.
Zurück zum Zitat Lezoche G, Baldarelli M, Guerrieri M, Paganini AM, De Sanctis A, Bartolacci S, et al. A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc. 2008;22(2):352–8.PubMedCrossRef Lezoche G, Baldarelli M, Guerrieri M, Paganini AM, De Sanctis A, Bartolacci S, et al. A prospective randomized study with a 5-year minimum follow-up evaluation of transanal endoscopic microsurgery versus laparoscopic total mesorectal excision after neoadjuvant therapy. Surg Endosc. 2008;22(2):352–8.PubMedCrossRef
59.
Zurück zum Zitat Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro Jr U, Sousa AH Jr Se, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7.PubMed Habr-Gama A, Perez RO, Nadalin W, Sabbaga J, Ribeiro Jr U, Sousa AH Jr Se, et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg. 2004;240:711–7.PubMed
60.
Zurück zum Zitat Morson BC, Bussey HJ, Samoorian S. Policy of local excision for early cancer in the colorectum. Gut. 1977;18:1045–50.PubMedCrossRef Morson BC, Bussey HJ, Samoorian S. Policy of local excision for early cancer in the colorectum. Gut. 1977;18:1045–50.PubMedCrossRef
61.
Zurück zum Zitat Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, et al. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol. 2010;17(2):441–7.PubMedCrossRef Callender GG, Das P, Rodriguez-Bigas MA, Skibber JM, Crane CH, Krishnan S, et al. Local excision after preoperative chemoradiation results in an equivalent outcome to total mesorectal excision in selected patients with T3 rectal cancer. Ann Surg Oncol. 2010;17(2):441–7.PubMedCrossRef
62.
Zurück zum Zitat Rich TA, Weiss DR, Mies C, et al. Sphincter preservation in patients with low rectal cancer treated with radiation therapy with or without local excision. Radiology. 1985;156:527–31.PubMed Rich TA, Weiss DR, Mies C, et al. Sphincter preservation in patients with low rectal cancer treated with radiation therapy with or without local excision. Radiology. 1985;156:527–31.PubMed
63.
Zurück zum Zitat Papillon J. Rectal and anal cancers: conservative treatment by radiation- an alternative to surgery. New York: Springer; 1982. Papillon J. Rectal and anal cancers: conservative treatment by radiation- an alternative to surgery. New York: Springer; 1982.
64.
Zurück zum Zitat Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002;54:142–9.PubMedCrossRef Gerard JP, Chapet O, Ramaioli A, Romestaing P. Long term control of T2-T3 rectal adenocarcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys. 2002;54:142–9.PubMedCrossRef
65.
Zurück zum Zitat Vuong T, Belliveau PJ, Michel RP, Moftah BA, Parent J, Trudel JL, et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum. 2002;45:1486–93.PubMedCrossRef Vuong T, Belliveau PJ, Michel RP, Moftah BA, Parent J, Trudel JL, et al. Conformal preoperative endorectal brachytherapy treatment for locally advanced rectal cancer: early results of a phase I/II study. Dis Colon Rectum. 2002;45:1486–93.PubMedCrossRef
66.
Zurück zum Zitat Ortholan C, Romestaing P, Chapet O, Gerard JP. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96–02 randomized trial. Int J Radiat Oncol Biol Phys. 2012;83(2):e165–71.PubMed Ortholan C, Romestaing P, Chapet O, Gerard JP. Correlation in rectal cancer between clinical tumor response after neoadjuvant radiotherapy and sphincter or organ preservation: 10-year results of the Lyon R 96–02 randomized trial. Int J Radiat Oncol Biol Phys. 2012;83(2):e165–71.PubMed
67.
Zurück zum Zitat Kim CJ, Yeadman CJ, Kapolla D, et al. Local excision of T2, and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234:352–259.PubMedCrossRef Kim CJ, Yeadman CJ, Kapolla D, et al. Local excision of T2, and T3 rectal cancers after downstaging chemoradiation. Ann Surg. 2001;234:352–259.PubMedCrossRef
68.
Zurück zum Zitat Lezoche E, Guerrieri M, Paganini AM, Feliciotti F. Long-term results of patients with pT2 rectal cancer treated with radiotherapy and transanal endoscopic microsurgical excision. World J Surg. 2002;26(9):1170–4.PubMedCrossRef Lezoche E, Guerrieri M, Paganini AM, Feliciotti F. Long-term results of patients with pT2 rectal cancer treated with radiotherapy and transanal endoscopic microsurgical excision. World J Surg. 2002;26(9):1170–4.PubMedCrossRef
69.
Zurück zum Zitat Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40.PubMedCrossRef Maas M, Beets-Tan RG, Lambregts DM, et al. Wait-and-see policy for clinical complete responders after chemoradiation for rectal cancer. J Clin Oncol. 2011;29(35):4633–40.PubMedCrossRef
70.
Zurück zum Zitat Weiser MR, Landmann RG, Wong WD, Shia J, Guillem JG, Temple LK, et al. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum. 2005;48(6):1169–75.PubMedCrossRef Weiser MR, Landmann RG, Wong WD, Shia J, Guillem JG, Temple LK, et al. Surgical salvage of recurrent rectal cancer after transanal excision. Dis Colon Rectum. 2005;48(6):1169–75.PubMedCrossRef
71.
Zurück zum Zitat Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.PubMedCrossRef Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med. 1990;322:352–8.PubMedCrossRef
72.
Zurück zum Zitat Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel project C-04. J Clin Oncol. 1999;17:3553–9.PubMed Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes’ B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel project C-04. J Clin Oncol. 1999;17:3553–9.PubMed
73.
Zurück zum Zitat Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–704.PubMedCrossRef Twelves C, Wong A, Nowacki MP, et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med. 2005;352:2696–704.PubMedCrossRef
74.
Zurück zum Zitat André T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;20:3732–8.CrossRef André T, Quinaux E, Louvet C, et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: final results of GERCOR C96.1. J Clin Oncol. 2007;20:3732–8.CrossRef
75.
Zurück zum Zitat • Jackson McCleary NA, Meyerhardt J, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12500 patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2009;27(15S):4010. This study using 10,499 patients aged <70 yrs and 2,170 aged <70 yrs in 6 phase III adjuvant trials from the ACCENT database suggests that patients >70 years do not receive the same benefit from combination and/or oral FU as those <70 years. • Jackson McCleary NA, Meyerhardt J, et al. Impact of older age on the efficacy of newer adjuvant therapies in >12500 patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol. 2009;27(15S):4010. This study using 10,499 patients aged <70 yrs and 2,170 aged <70 yrs in 6 phase III adjuvant trials from the ACCENT database suggests that patients >70 years do not receive the same benefit from combination and/or oral FU as those <70 years.
76.
Zurück zum Zitat Larsen SG, Wiig JN, Tretli S, Giercksky KE. Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age. Colorectal Dis. 2006;8(3):177–85.PubMedCrossRef Larsen SG, Wiig JN, Tretli S, Giercksky KE. Surgery and pre-operative irradiation for locally advanced or recurrent rectal cancer in patients over 75 years of age. Colorectal Dis. 2006;8(3):177–85.PubMedCrossRef
77.
Zurück zum Zitat Wolff HA, Conradi LC, Schirmer M, Beissbarth T, Sprenger T, Rave-Fränk M, et al. Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. Oncologist. 2011;16(5):621–31.PubMedCrossRef Wolff HA, Conradi LC, Schirmer M, Beissbarth T, Sprenger T, Rave-Fränk M, et al. Gender-specific acute organ toxicity during intensified preoperative radiochemotherapy for rectal cancer. Oncologist. 2011;16(5):621–31.PubMedCrossRef
78.
Zurück zum Zitat Lorchel F, Peignaux K, Créhange G, Bosset M, Puyraveau M, Mercier M, et al. Preoperative radiotherapy in elderly patients with rectal cancer. Gastroenterol Clin Biol. 2007;31(4):436–41.PubMedCrossRef Lorchel F, Peignaux K, Créhange G, Bosset M, Puyraveau M, Mercier M, et al. Preoperative radiotherapy in elderly patients with rectal cancer. Gastroenterol Clin Biol. 2007;31(4):436–41.PubMedCrossRef
79.
Zurück zum Zitat Pasetto LM, Basso U, Friso ML, et al. Determining therapeutic approaches in the elderly with rectal cancer. Drugs Aging. 2007;24(9):781–90.PubMedCrossRef Pasetto LM, Basso U, Friso ML, et al. Determining therapeutic approaches in the elderly with rectal cancer. Drugs Aging. 2007;24(9):781–90.PubMedCrossRef
80.
Zurück zum Zitat Fiorica F, Cartei F, Carau B, Berretta S, Spartà D, Tirelli U, et al. Adjuvant radiotherapy on older and oldest elderly rectal cancer patients. Arch Gerontol Geriatr. 2009;49(1):54–9.PubMedCrossRef Fiorica F, Cartei F, Carau B, Berretta S, Spartà D, Tirelli U, et al. Adjuvant radiotherapy on older and oldest elderly rectal cancer patients. Arch Gerontol Geriatr. 2009;49(1):54–9.PubMedCrossRef
81.
Zurück zum Zitat Ausili Cèfaro G, Genovesi D, Vinciguerra A, Augurio A, Di Tommaso M, Marchese R, et al. Effects of preoperative radiochemotherapy with capecitabine for resectable locally advanced rectal cancer in elderly patients. Tumori. 2012;98(5):622–9.PubMed Ausili Cèfaro G, Genovesi D, Vinciguerra A, Augurio A, Di Tommaso M, Marchese R, et al. Effects of preoperative radiochemotherapy with capecitabine for resectable locally advanced rectal cancer in elderly patients. Tumori. 2012;98(5):622–9.PubMed
82.
Zurück zum Zitat Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011;81(5):e735–41.PubMedCrossRef Margalit DN, Mamon HJ, Ancukiewicz M, Kobayashi W, Ryan DP, Blaszkowsky LS, et al. Tolerability of combined modality therapy for rectal cancer in elderly patients aged 75 years and older. Int J Radiat Oncol Biol Phys. 2011;81(5):e735–41.PubMedCrossRef
83.
Zurück zum Zitat Lange MM, van de Velde CJ. Faecal and urinary incontinence after multimodality treatment of rectal cancer. PLoS Med. 2008;5(10):e202.PubMedCrossRef Lange MM, van de Velde CJ. Faecal and urinary incontinence after multimodality treatment of rectal cancer. PLoS Med. 2008;5(10):e202.PubMedCrossRef
84.
Zurück zum Zitat Kim HJ, Boland PJ, Meredith DS, Lis E, Zhang Z, Shi W, et al. Fractures of the sacrum after chemoradiation for rectal carcinoma: incidence, risk factors, and radiographic evaluation. Int J Radiat Oncol Biol Phys. 2012;84(3):694–9.PubMedCrossRef Kim HJ, Boland PJ, Meredith DS, Lis E, Zhang Z, Shi W, et al. Fractures of the sacrum after chemoradiation for rectal carcinoma: incidence, risk factors, and radiographic evaluation. Int J Radiat Oncol Biol Phys. 2012;84(3):694–9.PubMedCrossRef
85.
Zurück zum Zitat Tokunaga M, Norman Jr JE, Asano M, Tokuoka S, Ezaki H, Nishimori I, et al. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950–74. J Natl Canc Inst. 1979;62:1347–59. Tokunaga M, Norman Jr JE, Asano M, Tokuoka S, Ezaki H, Nishimori I, et al. Malignant breast tumors among atomic bomb survivors, Hiroshima and Nagasaki, 1950–74. J Natl Canc Inst. 1979;62:1347–59.
86.
87.
Zurück zum Zitat Curtis RE, Freedman DM, Ron E, et al. editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH publication no. 05–5302. Bethesda: National Cancer Institute; 2006. Available via http://seer.cancer.gov/publications. Curtis RE, Freedman DM, Ron E, et al. editors. New malignancies among cancer survivors: SEER cancer registries, 1973–2000. NIH publication no. 05–5302. Bethesda: National Cancer Institute; 2006. Available via http://​seer.​cancer.​gov/​publications.
88.
Zurück zum Zitat Lönn S, Gilbert ES, Ron E, et al. Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. Canc Epidemiol Biomarkers Prev. 2010;19(2):464–74.CrossRef Lönn S, Gilbert ES, Ron E, et al. Comparison of second cancer risks from brachytherapy and external beam therapy after uterine corpus cancer. Canc Epidemiol Biomarkers Prev. 2010;19(2):464–74.CrossRef
89.
Zurück zum Zitat Bouvier AM, Jooste V, Bonnetain F, et al. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer. 2008;113(4):879–86.PubMedCrossRef Bouvier AM, Jooste V, Bonnetain F, et al. Adjuvant treatments do not alter the quality of life in elderly patients with colorectal cancer: a population-based study. Cancer. 2008;113(4):879–86.PubMedCrossRef
90.
91.
Zurück zum Zitat Cesari M et al. Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr. 2006;83:1142–8.PubMed Cesari M et al. Frailty syndrome and skeletal muscle: results from the Invecchiare in Chianti study. Am J Clin Nutr. 2006;83:1142–8.PubMed
92.
Zurück zum Zitat Charlson ME et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.PubMedCrossRef Charlson ME et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis. 1987;40:373–83.PubMedCrossRef
93.
Zurück zum Zitat Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–31.PubMedCrossRef Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol. 2007;25:1824–31.PubMedCrossRef
94.
Zurück zum Zitat Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.PubMed Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc. 1991;39(2):142–8.PubMed
95.
Zurück zum Zitat Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–7.PubMed Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582–7.PubMed
96.
Zurück zum Zitat Chen H, Overcash J, Extermann M, et al. Comprehensive geriatric assessment in elderly cancer patients: impact on overall survival and progression free survival. Poster P76. American Geriatric Society Meeting. Philadelphia, 1999; May 19–23. Chen H, Overcash J, Extermann M, et al. Comprehensive geriatric assessment in elderly cancer patients: impact on overall survival and progression free survival. Poster P76. American Geriatric Society Meeting. Philadelphia, 1999; May 19–23.
97.
Zurück zum Zitat Saliba D et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–9.PubMedCrossRef Saliba D et al. The Vulnerable Elders Survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc. 2001;49:1691–9.PubMedCrossRef
98.
Zurück zum Zitat Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol. 2007;25:1936–44.PubMedCrossRef Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol. 2007;25:1936–44.PubMedCrossRef
Metadaten
Titel
Colorectal Cancer in the Elderly: How Do We Tailor Treatment with Chemotherapy and Radiotherapy Most Appropriately?
verfasst von
Demetris Papamichael
Rob Glynne-Jones
Publikationsdatum
01.06.2013
Verlag
Current Science Inc.
Erschienen in
Current Colorectal Cancer Reports / Ausgabe 2/2013
Print ISSN: 1556-3790
Elektronische ISSN: 1556-3804
DOI
https://doi.org/10.1007/s11888-013-0163-8

Weitere Artikel der Ausgabe 2/2013

Current Colorectal Cancer Reports 2/2013 Zur Ausgabe

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Safety of Simultaneous Bowel and Liver Resections for Colon and Rectal Cancer

Colorectal Cancer Hepatic Metastases (KK Tanabe, Section Editor)

Use of Chemotherapy in the Resection of Liver Metastases of Colorectal Cancer

Localized Rectal Cancer (R Glynne-Jones, Section Editor)

The Role of Enhanced Recovery After Surgery for Rectal Cancer

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.